Objective. The objective of this study was to examine 5-year change in cortical hand BMD in female RA patients with established disease. Further, possibly baseline predictors of 5-year loss in digital X-ray radiogrammetry (DXR)-BMD were studied.
Introduction
Periarticular bone loss is an early characteristic feature of RA visible on radiographs and, together with erosions, considered a hallmark of the disease [1] . Inflammatory activation of the osteoclast is involved in both features. Studies support that cytokines such as TNF-a, IL-1, IL-6, macrophage colony-stimulating factor and RANK ligand activate the osteoclast that causes osteoporosis (localized and generalized) and erosions [2] [3] [4] .
Quantitative hand bone loss can be measured by DXA-BMD, which measures the total amount of local bone [5] and digital X-ray radiogrammetry (DXR), which measures cortical bone [6] . The advantage of DXR is that BMD can be analysed from hand radiographs, often taken routinely of RA patients in daily clinical practice. Previous studies suggest that DXA-measured bone loss only takes place during the first 2-3 years after disease start [7] [8] [9] , whereas one study suggests that DXR-measured loss occurs through the whole disease course [9] . However, there is limited information concerning hand bone loss in established RA. Inflammation of the joints is not restricted to the early phase of the RA disease, but may be present during the entire disease course [10] . Hence, theoretically one could also consider applying hand bone as an outcome measure in established RA. The main objective of this multicentre observational study was to examine 5-year change in hand DXR-BMD in RA patients with established disease and possibly identify baseline predictors of 5-year change in DXR-BMD.
Methods

Patients
The original cohort consisted of 150 women with established RA who were recruited from rheumatology clinics in Amsterdam, the Netherlands; Truro, UK; and Oslo, Norway. At baseline, 50 patients were consecutively included per centre and inclusion criteria were: female sex, age 50-70 years and RA disease duration 55 years [11] . Hand BMD measured with DXR was performed in 135 of the original cohort at baseline [12] . We now present the 5-year follow-up data for DXR-BMD for 85 of these patients (29 patients from Amsterdam; 26 from Truro; and 30 from Oslo). A flow chart of the patients is depicted in Fig. 1 . Disease activity at baseline was assessed by joint counts (28 tender and 28 swollen joint counts), patient's and physician's global assessment of disease activity and by acute-phase reactants. The 28-joint disease activity score (DAS-28) was computed based on ESR [13] . The study was approved by the local medical ethics committees of the three centres, and all patients were informed and signed a patient consent form.
Radiographs and DXR-BMD analyses DXR (Sectra, Linkö ping, Sweden) was used to measure hand BMD on bilateral hand radiographs taken in postero-anterior view. DXR is a computer version of the traditional radiogrammetry technique [14] and has previously been described in detail [6] . On hand radiographs, the computer automatically recognizes regions of interest around the narrowest part of the second, third and fourth metacarpal bone and measures cortical thickness, bone width and porosity 118 times per centimetre. DXR-BMD is defined as: c Â VPA comb Â (1 À p), where c is a density constant, VPA is cortical volume per area and p is porosity. To avoid bias regarding dominant and non-dominant hands and to achieve better precision, we used the mean of both hands [15] . If the radiograph from one hand could not be analysed, we used the radiograph from the available hand for analyses at both time points. At baseline, all radiographs were conventional films and DXR-BMD were analysed with Pronosco X-posure 2.0 (Sectra, Linkö ping, Sweden). Short-time precision [coefficient of variation (CV%)] for Pronosco X-posure based on duplicate hand radiographs with reposition between each measurement in healthy individuals has been found to be 0.28% for mean of both hands [9] . At 5-year follow-up, DXR-BMD for the radiographs from Amsterdam (conventional) and Truro (digitized and printed out) were analysed with the same Pronosco X-posure 2.0 equipment, while the radiographs from Oslo were digitized and analysed with dxr-online (Sectra, Sweden). The same algorithm was used for calculating DXR-BMD both in Pronosco X-posure and dxr-online (Sectra). However, analysing digitized radiographs has been shown to be more influenced by the radiographic equipment than conventional radiographs [16] [17] [18] . Seven patients' radiographs failed DXR-BMD analyses due to severely damaged joints or metal implants at 5-year follow-up. These patients showed a trend towards a longer disease duration www.rheumatology.oxfordjournals.org (20 vs 13.5 years, P = 0.12) and older age (59.6 vs 62.4 years, P = 0.27). The baseline radiographs of the hands and wrists were scored according to the van der Heijde modified Sharp score (vdHSS) by a trained observer (P.B.) [19] .
Statistical methods
The analyses were performed using SPSS 14 statistics package (SPSS inc, Chicago IL, USA). Baseline characteristics were described using median and interquartile range (IQR) for continuous variables and percentage for counts. Independent groups were compared using MannWhitney U-test for continuous variables, 2 -tests for dichotomous variables and Kruskal-Wallis test for differences between centres. DXR-BMD change was calculated as the percentage difference between the follow-up value and the baseline value, and bone loss over time was expressed as a negative value. The individual 5-year DXR-BMD changes were depicted in cumulative probability plots [20] . Possible predictors for 5-year DXR-BMD loss were examined by univariate linear regression analyses. The independent variables with a P 4 0.20 were included in multivariate linear analyses with 5-year changes in DXR-BMD as the dependent variable. The final multivariate model was obtained by enter procedure and standard diagnostic tests of model assumptions and residuals were routinely performed. All tests were two-sided and P 4 0.05 was considered to be statistically significant.
Results
Baseline characteristics
Baseline characteristics comparing patients with and without 5-year DXR-BMD measurements are presented in Table 1 , and the patient flow is presented in Fig. 1 . The 85 included patients were younger, had a significantly lower ESR, HAQ and they also had significantly higher DXA of the total hip compared with those who were not included (n = 65) from the original study (Table 1 ). The two groups were comparable regarding disease duration, positive RF, DAS-28 and use of DMARDs, prednisolone and bone-protective treatment. There were no significant differences in the number of patients from the different centres available for follow-up at 5 years (29 patients from Amsterdam; 26 from Truro; and 30 from Oslo; P = 0.88, 2 -tests).
Baseline and follow-up treatments are summarized in Table 1 . Overall, 52% of the patients used boneprotective treatment (defined as bisphosphonates, oestrogens or raloxifen) during follow-up. The patients receiving bone-protective treatment at baseline had similar DAS-28 to those who did not (4.8 vs 4.5, P = 1.0). None of the patients was treated with teriparatide or calcitonin. Anti-TNF-a therapy was used by 19% of the patients. 
DXR-BMD change during the follow-up period
The mean (95% CI) baseline DXR-BMD for all patients was 0.46 (0.44, 0.48) g/cm 2 and the median (IQR) 5-year DXR-BMD change was À6.7% (À11.2 to À2.82%). The individual 5-year DXR-BMD losses stratified for centre are depicted in a cumulative probability plot (Fig. 2) . The median (IQR) 5-year DXR-BMD change in Amsterdam, Truro and Oslo was À5.1% (À10.7 to À2.4%), À8.1% (À12.4 to À5.2%) and À6.9% (À10.7 to À2.8%), respectively. There were no statistically significant differences between the centres (P = 0.19, Kruskal-Wallis test). vdHSS change during the 5-year follow-up period was median 8 U (IQR 0-16.5 U). The correlation between 5-year change in hand DXR-BMD and vdHSS was À0.24 (P = 0.04).
Associations between 5-year DXR-BMD change and baseline characteristics and prediction of hand bone loss
The associations between 5-year change in DXR-BMD and baseline variables and treatment during follow-up are presented in Table 2 . Five-year DXR-BMD loss was significantly associated with lower age, positive RF, elevated CRP, HAQ and DAS-28 in univariate linear regression analyses. Baseline DAS-28 was maintained as an independent predictor of 5-year change in DXR-BMD in the final multivariate linear regression model. The final model explained 31% of the variation (R 2 ) in DXR-BMD change and was corrected for age, centre and use of bone-protective agents. The effect of disease activity on hand bone loss is illustrated by a cumulative probability plot depicting the 5-year DXR-BMD change stratified for high (DAS-28 > 5.1) vs low and moderate disease activity (Fig. 3) . DAS-28 of 5.1 is the cut-off point between moderate and high disease activity and was therefore selected as a cut-off for high disease activity [21] .
Discussion
The main finding in this study was that baseline disease activity independently predicted hand BMD loss in postmenopausal patients with established, severe RA. Only a few studies have examined associations between disease 
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High disease activity predicts hand bone loss in RA factors and hand bone loss in RA, but most of these studies have focused on early disease [7-9, 15, 22, 23] . The change in DXA-BMD hand and DXA bone mineral content (BMC) has been found to be inversely correlated with elevated baseline CRP levels and the presence of RF [7, 8, 15] . However, loss of DXA-BMD and DXA-BMC has been suggested to occur only in patients with disease duration of <2-3 years and may limit the use of hand DXA-BMD in established disease [7] [8] [9] . Degenerative bone changes and increased inflammation in the small joints of the hand in the first years of the disease have been suggested partly to explain this finding [5, 7, 9] . The fact that DXR-BMD and DXA-BMD are based on different techniques and the precision of the DXR method [18, 24, 25] is superior to that of the DXA method [26] [27] [28] may also contribute to this difference.
There are a few studies concerning disease activity as a predictor for DXR-BMD. In early RA, both loss of DXR-BMD and DXR metacarpal cortical index have been predicted by high CRP [22, 29] , high ESR and anti-CCP [23, 30] . Only one previous study has shown that high DAS-28 predicted DXR-BMD loss in established RA [9] . This previous study only had a follow-up of 2 years, but included a larger number of patients than the current study.
The DAS-28 levels were improved during the 5-year follow-up from 4.8 to 3.8 (P < 0.001). The main reason for this is probably the introduction of anti-TNF therapy and a more aggressive treatment with combination of DMARDs. Despite improvement in DAS-28 during the follow-up period, the patients experienced a significant decline in cortical hand BMD, suggesting that this bone loss is chronic and progressive.
Another observation in the present study was that the youngest age group lost more hand BMD than the oldest age group. In order to look at the possible impact of menopause on hand bone loss, we dichotomized the age into below and above 60 years, this also coincided with the median age. An earlier 10-year longitudinal study has suggested that the menopause, and not age per se, was determining the start of a period with increased rate of bone loss [31] . However, some studies suggest that bone loss increases after menopause and then declines with age [32] , while others suggest an increased constant bone loss [31] . This study might support that bone loss is greater in the first years after menopause [32] , and suggest that not only increased generalized bone loss is observed in early post-menopausal women, but also that local hand bone loss is elevated. However, this result may be biased by the fact that the drop-outs were older than the participants (64 vs 60 years, P < 0.001).
The effect of medical treatment on bone was difficult to evaluate in this study due to the observational study design and the unstandardized patient treatment. In RA patients, adverse effects on bone by corticosteroids are of clinical importance [33, 34] . However, suppressing inflammation by corticosteroids has been found to increase hand DXR-BMD in two studies [22, 35] , which may suggest that the anti-inflammatory effect overweighs the negative corticosteroid effect on bone. In the present study, the use of corticosteroids was not associated with cortical bone loss, which might be due to the treatment with bone-protective agents. Use of bone-protective agents during follow-up was non-significantly associated with a decreased loss in DXR-BMD (Table 2) , which may suggest that this treatment might have a beneficial effect not only on generalized bone loss and fractures but also on cortical hand bone loss in RA. Previous studies are conflicting in their results as to the effect of anti-resorptive treatment on hand BMD [22, 36, 37] . Anti-TNF-a therapy has also been found to decrease bone loss in early RA patients [22, 38] . In this study, treatment with anti-TNF-a therapy was not associated with DXR-BMD change, which might be explained by the long disease duration, high disease activity and the low proportion (19%) of users of anti-TNF-a therapy as well as confounding by indication.
The main limitation of this study was that the 5-year follow-up radiographs were analysed in three different ways, due to difficulties of analysing DXR-BMD in the three different centres as mentioned under the 'Methods' section. However, DXR-BMD change did not differ between the three centres and the 5-year DXR-BMD median percentage changes for all centres were À6.7%, which exceeds the possible source of error for the analysing methods. Based on these observations, we do not think that the bias of these different analyses affects the main conclusion. Another limitation to the DXR method is that it cannot be applied to radiographs of RA patients with severe joint damage. In the present study, 10 and 7% of the baseline and follow-up radiographs, respectively, could not be analysed for this reason.
Conclusion
RA patients with established disease experienced substantial cortical hand bone loss. This bone loss was independently predicted by high disease activity.
This finding indicates that increased disease activity leads to localized bone loss in long-standing RA, which supports the importance of tight control and aggressive anti-inflammatory treatment also in patients with established disease.
Rheumatology key messages
. High disease activity is an important predictor for hand bone loss in patients with long-standing, destructive RA. . Tight control and anti-inflammatory treatment is important also in patients with long-standing, destructive RA.
